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Abstract 
Background Dose-optimisation studies as precursors to clinical trials are rare in stroke rehabilitation.  
Objective To develop a rule-based, dose-finding design for stroke rehabilitation research.  
Design 3+3 rule-based, dose-finding study. Dose escalation/de-escalation was undertaken according to pre-set rules and a mathematical 
sequence (modified Fibonacci sequence). The target starting daily dose was 50 repetitions for the first cohort. Adherence was recorded by an 
electronic counter. At the end of the 2-week training period, the adherence record indicated dose tolerability (adherence to target dose) and the 
outcome measure indicated dose benefit (10% increase in motor function). The pre-set increment/decrease and checking rules were then applied 
to set the dose for the subsequent cohort. The process was repeated until pre-set stopping rules were met.  
Participants Participants had a mean age of 68 (range 48–81) years, and were a mean of 70 (range 9–289) months post stroke with moderate 
upper limb paresis.  
Model task A custom-built model of exercise-based training to enhance ability to open the paretic hand.  
Outcome measure Repetitions per minute of extension/flexion of paretic digits against resistance.  
Analysis Usability of the pre-set rules and whether the maximally tolerated dose was identifiable.  
Results Five cohorts of three participants were involved. Discernibly different doses were set for each subsequent cohort (i.e. 50, 100, 167, 251 
and 209 repetitions/day). The maximally tolerated dose for the model training task was 209 repetitions/day.  
Conclusions This dose-finding design is a feasible method for use in stroke rehabilitation research. 
 
Keywords: Stroke rehabilitation; Dose finding; Physical therapy; Upper limb 
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<A>Introduction 
Recommendations for higher doses of physiotherapy in stroke rehabilitation, based on findings from meta-analyses [1], are questioned by 
findings that higher doses may not always produce better recovery [2–5]. This could be because clinical recommendations based on meta-
analyses of dose [6] may be insufficiently nuanced in respect of potential influential factors on dose response. Consideration of potential 
influential factors (e.g. type of intervention, time after stroke, severity of paresis) is difficult within meta-analysis because reports of primary 
trials do not always provide sufficient information [7]. Indeed, removal of the potential confounder of type of therapy diminishes the relationship 
between higher dose and better outcome [8]. These clinical findings are echoed in experimental studies of motor recovery in animal models and 
motor learning in healthy adult humans. Higher doses of therapy/training do not always provide better results [9–11].  
In other areas of health care, the optimal therapeutic dose of specific interventions is frequently determined before undertaking clinical 
efficacy trials. Such dose-optimisation studies are needed for specific stroke rehabilitation interventions [12–14]. There are several parameters of 
dose to consider [15], including the maximum tolerable dose (MTD) and recommended Phase II dose (RPTD). These are listed and defined in 
Appendix 1 [16].  
Pharmaceutical research employs two main dose-optimisation designs: dose-ranging and dose-finding [17]. Dose-ranging studies identify the 
response to, and safety of, a number of pre-specified doses identified through early-phase research. Dose-finding studies are classified as 
adaptive designs as they allow exploration of the dose–response relationship whilst minimising sample size and maintaining safety of 
participants [18–20].  
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The aim of this investigation was to develop a dose-finding design for stroke rehabilitation research, rather than to identify the MTD or 
RPTD of exercise-based physiotherapy. The specific objectives were: 
(1) to determine if all the features of the (pharmaceutical) dose-finding design are viable; and 
(2) to determine if the dose-finding design can identify the MTD and RPTD of a model of exercise-based therapy.  
 
A model training task was used to minimise the possibility that the results of the methodological development investigation reported here 
could be used to inform the prescribed dose of exercise-based physiotherapy. If the design is feasible, it can be used in subsequent dose-ranging 
studies to check the RPTD for evaluation in later clinical efficacy trials.  
 
<A>Methods  
<B>Design 
A single-arm, 3+3 rule-based, dose-escalation design (Fig. 1) was adapted for a motor rehabilitation intervention. The advantage of this 
design is that it provides an acceptable level of precision in finding the MTD, finds the RPTD, minimises sample size, and makes no prior 
assumptions about the dose–response relationship [16,18,20–22].  
 
<insert Fig 1 near here> 
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The study began with the first cohort (n=3) exercising at the target starting dose, 50 repetitions, for 5 days/week for a 2-week period (10 
training days; Fig. 1). The second and subsequent cohorts exercised at a target dose set in accordance with the nine pre-set rules (see below) and 
the modified Fibonacci sequence (mFBS) (Table 1). The mFBS allows for rapid increase from the initial low dose for which minimal adverse 
consequences are likely. As dose increases, the occurrence of adverse consequences is likely to be greater, but the incremental increase is 
smaller. The mFBS also reduces the chance of implementation of subtherapeutic doses [23], and provides an adequate spread of doses for 
estimation of the dose–response relationship [22].  
 
<insert Table 1 near here> 
 
<C>Pre-set rules 
Two definitions were used. A tolerable dose was defined as one where two or more participants adhered to the set dose for that cohort and, at 
most, only one participant experienced an adverse consequence. If a participant was unable to adhere to the target dose due to reasons unrelated 
to the design (e.g. hospital appointment) for ≤3 days over the 2-week period, they were still considered adherent. A beneficial dose was defined 
as an increase in the score of the dose-benefit measure (details below) by ≥10% over the training period (for at least two participants in a cohort).  
The dose-setting rules (Rules 1 to 5), possible scenarios and their consequent actions were applied for each cohort at the assessment at the 
end of the training period (Fig. 1): 
1. The target dose was not achieved by all three participants. The consequent action was to decrease the dose by 50% of the previous increment for 
the subsequent cohort (Fig. 1). 
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2. The target dose was tolerable and beneficial for a cohort. The consequent action was to increase the dose for the subsequent cohort (Fig. 1). 
3. The target dose was not tolerable for a cohort. If this occurred, Rule 6 was applied (see „Checking rules‟ below and Fig. 1).  
4. If the target dose was tolerable for a cohort but not beneficial: 
(a) if there was no change in the dose-benefit measure between the pre-training and post-training points for at least two of three 
participants, the consequent action was to implement Rule 7 (see „Checking rules‟ below and Fig. 1).  
(b) If there was a decrease in the dose-benefit measure between the pre-training and post-training points for at least two of three 
participants, the dose for the subsequent cohort was decreased by 50% of the previous increment (Fig. 1).  
5. If a dose was decreased for a cohort and then deemed tolerable and beneficial, the action for the subsequent cohort was to increase the dose by 
67% (Sequence Point 3 of the mFBS, Table 1) of the previous increment (Fig. 1). 
 
The checking rules (Rules 6 and 7) were applied to reduce the possibility of a dose being deemed not tolerable or not beneficial because of 
individuals, rather than the target dose itself: 
6. If the dose was not tolerable for two of three participants, the next cohort received the same target dose. If this dose was not tolerable for two 
participants in the second cohort, the next cohort was decreased by 50% of the last increment (Fig. 1).  
7. If a particular dose was tolerable but not beneficial for at least two participants, the mFBS informed increase of the dose for the subsequent 
cohort. If that second cohort also did not experience at least a 10% improvement in the outcome measure, the stopping rules were considered. 
 
The stopping rules (Rules 8 and 9) were as follows. 
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8. If after at least one beneficial dose, the subsequent two target doses were tolerable but no further gains in motor function were made in at least 
two participants in each of the two consecutive cohorts, the study was stopped (Fig. 1). 
9. If the dose difference between two cohorts was ≤10%, the study was stopped (Fig. 1). 
 
<B>Participants and sample size 
Participants were recruited from stroke survivor support groups. Each participant provided informed consent and: 
 was aged 18 years or more;  
 had received a clinical diagnosis of stroke at least 6 months previously, and thus was in the so-called „chronic phase‟ when spontaneous recovery 
was not expected to confound response to the model of exercise-based physiotherapy used as the training task in this investigation; 
 had the ability to open and close the paretic hand six times in 1 minute but was unable to do this 25 times in 1 minute when an extra-extra-light 
resistance band (DIGI-EXTEND) was placed around fingers and thumb; 
 was able to imitate actions with the less-paretic upper limb. The researcher sat alongside the potential participant and performed the model 
training task (details below) five times using the extra-extra-light resistance band. The participant then performed the model training task five 
times with the less-paretic upper limb. Accuracy of imitation was scored as follows: 2 points = correctly reproduced; 1 point = incorrect 
reproduction; and 0 points = task not reproduced [24]; and 
 was discharged from statutory stroke rehabilitation. 
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Target sample size is not usually pre-defined for dose-finding studies [19]. The final sample size is determined by the response of subsequent 
cohorts to the target dose. In pharmaceutical dose-finding studies, the reported sample sizes are generally between 12 and 40 [25]. 
 
<B>Model training task, starting dose, adherence and study procedure for participants 
The training task was devised as a model of exercise-based physiotherapy to avoid the potential confounders of: (a) different training tasks 
for each participant; and (b) familiarity/prior training with the training task (Box 1). It focused on training synergistic extension/abduction and 
flexion/adduction of the paretic fingers and thumb against a tailored resistance in left and right workspace. The equipment (Fig. 2) comprised a 
custom-made wooden stand with two vertical tripods and resistance-graded rubber bands (DIGI-EXTEND). An elastic band was placed on the 
top one-third of one of the tripods. Participants placed their paretic fingers and thumb inside the band and then moved it on to the other tripod: 
this was one repetition. Moving it back to the first tripod counted as a second repetition, and so on. Each day, they performed the target number 
of repetitions (dose), which was split across the day if necessary.  
 
<insert Box 1 and Fig 2 near here> 
 
Exercise-based training is comprised of several dose components (Appendix 1). All of these were controlled apart from the amount (in this 
case, repetitions per session), as this was the dose component of interest. The training duration was 2 working weeks (10 days), and frequency 
was every working day. Intensity (effort required to perform the task) was set individually for each participant to maximise equivalence. 
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On their first trial day, the training intensity was set for each participant for 2 weeks. Intensity was determined as the resistance band with 
which an individual was able to complete six repetitions in 1 minute. Setting intensity began with the extra-light band. If this was too difficult, 
they were given the extra-extra-light band. Alternatively, if the extra-light band was too easy, the light band was tried, then the medium and so 
on until the correct band was identified. 
To set the starting dose, it was considered that this is usually based on precursor studies that establish the safe minimal effective dose for 
pharmaceutical dose-finding studies (Appendix 1). Such precursor studies are unavailable for stroke rehabilitation. As such, the starting dose for 
the present study considered that experimental studies of animal models of stroke indicate that a beneficial dose may be between 240 [26] and 
400 [27–31] daily repetitions, and that approximately 300 daily repetitions may be tolerable for stroke survivors [32,33]. It was also considered 
that the dose-setting rules allowed for rapid increments of the target dose, but it was necessary to ensure that the design feasibility was tested. 
Consequently, the conservatively low starting dose of 50 repetitions was chosen.  
Adherence to target dose, tolerability was assessed via an electronic counter (Fig. 2). The number of repetitions and time spent in self-
practice was recorded and stored electronically in a memory card. At the beginning of a training day, the participant switched on the counter and 
then pressed a red button to initialise the recording card. After each repetition, they pressed a black button. The counts were displayed on the 
integral monitor. At the end of each session, participants recorded the number of repetitions on a paper form to safeguard against any challenges 
with the memory card.  
The study procedure began on the participants‟ first training day (Day 1) when they attended the Movement Laboratory for baseline 
measurement. The intensity of the training task was then set for each individual (described above). The participants‟ first training session was 
supervised by the researcher to ensure that the training task and recording of repetitions was undertaken correctly. On Days 2 to 7, participants 
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self-trained in their homes for 5 days. Participants returned to the Movement Laboratory on Day 8 for a check of how they were performing the 
task, recording repetitions, and to discuss any concerns or questions. They then self-trained at home for 5 of the remaining 6 days. On the day 
after the last training day (Day 14), participants attended the Movement Laboratory for outcome measurement, if possible. Up to 7 days were 
allowed in the ethically approved protocol for this post-training visit to avoid attrition due to public holidays, illness etc.  
 
<B>Dose-benefit measure 
The Cando Digit-Extend device (DIGI-EXTEND) was used to measure the number of repetitions in 1 minute of extension/flexion of fingers 
and thumb against the lightest resistance band whilst participants sat at a table on a dining-type armless chair. This measure was chosen as it 
required the same finger extension movement of the trained task, but was different in that no transportation of the hand was required horizontally 
across the workspace.  
 
 
 
<B>Adverse consequences 
If participants experienced any adverse occurrences, such as discomfort, pain and fatigue, on any of the training days, they noted these on the 
dose-monitoring form. The researcher also specifically asked them about adverse occurrences during their visits to the Movement Laboratory.  
 
<B>Analysis 
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Dose-finding design feasibility was assessed through: time required to recruit participants and complete the study; and usability of the pre-set 
rules. 
MTD was identified in accordance with the definition provided in Appendix 1. RPTD was identified by: (a) plotting the dose adherence rate 
by cohort; and (b) estimating the dose–response relationship using two standard curves (linear and quadratic), and using the one that provided 
the best fit [34]. Best goodness of fit was defined as the curve with the highest R
2
 (coefficient of determination) value, and RPTD is the 
maximum y-axis value for the curve. A non-parametric curve was plotted as a graphical gauge. 
 
<A>Results 
Table 2 provides details of participants‟ characteristics at baseline. In summary, the mean age of the 15 participants was 68 (range 48 to 81) 
years and the mean time post stroke was 70 (range 9 to 289) months.  
 
<insert Table 2 near here> 
 
<B>Feasibility of the design 
<C>Time required 
The trial recruitment period started in March 2014 and data collection ended in February 2015.  
 
<C>Pre-set rules 
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Application of the mFBS with the dose-setting rules determined different target doses for subsequent cohorts [i.e. differences >10% (Table 3)]. 
Five cohorts were included. A sixth cohort was not recruited as the set dose would have been 237 repetitions. However, only 14 repetitions 
separated doses of 251 (Cohort 4) and 237, which was <10% of the difference (Table 3). Consequently, the trial was stopped at that point (Rule 
9). The pre-set checking rules were not required during this study. 
 
<insert Table 3 near here> 
  
Adherence to target dose was important for the application of the pre-set rules. One participant reported getting confused about the correct 
procedure to switch the counter on and off. Two other participants reported that the small visual display and the sequential procedure needed to 
store data on the card had caused them to make errors in recording over a 5-day period. However, there was acceptable agreement between the 
paper-based and counter repetitions record, with a correlation coefficient of r=0.86 (p<0.001) (Fig. 2).  
None of the participants reported an adverse consequence from participation in the model training task. 
 
<B>Identification of the maximal tolerated dose  
For the model training task used in this design feasibility study, MTD was determined as 209 repetitions/day (Table 3).  
 
<B>Identification of the recommended Phase II dose  
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Fig. 3 provides plots of the dose–response relationship in relation to: (a) the subjective report of number of repetitions; (b) the objective 
report of number of repetitions; and (c) the target repetitions. The best fit of data was found with a quadratic equation. Fig. 3 suggests that RPTD 
for the model training task used in this design feasibility study was approximately 160 repetitions/day.  
 
<A>Discussion 
This dose-finding design was found to be feasible, and able to identify MTD and RPTD. However, pursuing dose finding on the basis of the 
current values is not directly applicable as the purpose of this study was to test the feasibility of the design, not to provide data to inform 
subsequent dose-ranging studies of the model training task as a potential intervention for future clinical practice. To do so would lead to false 
impressions that the dose parameters identified in this study are of relevance for application of clinical interventions to stroke survivors. The 
investigation reported here represents methodological development.  
Strengths of the design tested are that the mFBS escalation procedure provided sufficient distance between doses, and the trial stopping rules 
avoided the provision of similar doses for different cohorts. However, requiring at least 10% difference in the number of repetitions between 
subsequent cohorts could have been too high. In detail, Cohort 4 were set 251 daily repetitions but this was not tolerable; as such, Cohort 5 were 
set 209 daily repetitions which was found to be tolerable. Following the escalation sequence, the subsequent dose would have been 237 daily 
repetitions but this was not >10% different from the intolerable 251. Therefore, a stopping rule was triggered and the study was stopped. 
Following the investigative design reported here, MTD was therefore set at 209 repetitions. However, it actually lies somewhere between 209 
and 251 repetitions for the model training task. An MTD value between 209 and 251 is imprecise. Therefore, it could have been better to use a 
5% difference between doses in the stopping rules. 
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The approach of identifying the dose of rehabilitation intervention before conducting clinical efficacy trials is uncommon [8,12,14]. Previous 
studies have mainly used dose-ranging designs with pre-specified doses with parallel groups [35] or intervention crossover [36]. The authors are 
only aware of one previous dose-finding study of a rehabilitation intervention, but a different design was used to that reported here [37]. Unlike 
the present study, the starting dose was relatively high (only two cohorts before MTD was found: n=6), subsequent doses were not based on 
benefit as well as report of adverse consequences, each cohort received four different doses, de-escalation did not appear to have been 
considered and checking rules were not applied. Therefore, the earlier design only yielded MTD. No dose–response information was generated 
and therefore RPTD cannot be determined from the design used. Interestingly, the study reported here found that RPTD was 64% to 76% of 
MTD. In clinical practice, this represents a considerable resource saving compared with provision of MTD. Therefore, the design reported here 
may have advantages over that reported earlier [37]. 
A limitation of the current study was that problems were found with the counter used. Although this not a problem with the study design per 
se, it does mean that subsequent dose-finding studies need a better way of monitoring adherence to the target dose. 
In any clinical research usage of the dose-finding design developed within this investigation, it will be important to ensure that participants 
are sufficiently homogeneous for the identified MTD and RPTD to be meaningful. However, for the methodological development investigation 
reported here, homogeneity in terms of, for example, time post stroke was not such a strong consideration. The principle that guided selection of 
participants for the present methodological investigation was that they were able to perform the model training task and had potential to benefit 
from it. Indeed, the participant selection criteria enabled the required testing of the dose-finding design for stroke rehabilitation research. The 
investigation reported here does not provide RPTD for subsequent use in stroke rehabilitation research or clinical practice. Rather, it provides an 
additional methodological tool to add to knowledge of stroke rehabilitation. 
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Although the final sample size of this investigation is relatively small compared with clinical efficacy trials, the number of participants (15) 
is within the range of 12 to 40 considered sufficient for pharmaceutical dose optimisation [25]. Regardless of the cohort size, it is important to 
follow a dose-escalation study with a dose-ranging study for confirmation of estimated dose before undertaking a clinical efficacy trial 
[20,38,39]. This would entail randomising participants to one of several doses around RPTD. Such dose-ranging studies have already been used 
in stroke rehabilitation research [35].  
The next step for development of this dose-finding design is to test its application for identification of MTD and RPTD of task-orientated 
training for stroke survivors. Success is promised by a different form of dose escalation already conducted for exercise therapy [37].  
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Appendix 1 
Definitions of dose-finding elements used in this study 
Dose components 
Dose of exercise-based therapy is comprised of several components generally known as:  
a. intensity (effort); 
b. amount (quantity per session); 
c. frequency (number of sessions per day); and 
d. duration (number of weeks).  
It is just as important to specify the levels of each component of exercise-based therapy as it is for 
constituents of a pharmaceutical compound. Not doing so restricts replication of research and 
transferability of research findings to clinical practice.  
Dose endpoints [16] 
a. The maximum tolerable dose is the highest dose at which adverse consequences are still 
acceptable for participants. 
b. The minimum effective dose is the first dose with a clinically relevant effect that is significantly 
different from placebo. 
c. Recommended Phase II dose is that to be used in subsequent efficacy studies. 
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Fig 1. Flowchart to illustrate the dose-finding design. Tolerable dose is where two or more participants adhered to the set dose for that cohort 
and, at most, only one participant experienced an adverse consequence. Beneficial dose is where two or more participants demonstrated an 
increase of at least 10% in the outcome measure over the course of the training period. 
 
 
Fig. 2. (a) Training task. Participants inserted fingers and thumb of paretic hand into the elastic band. They opened their hand to take the band 
from one tripod and place it on the other. This was one repetition. Next, extended fingers and thumb had to replace the band on the first tripod. 
After each repetition, the participant pressed the black button on the counter to provide a digital record. (b) Agreement between objective 
(OBM, counter) and subjective (SRM, paper-based) records of repetitions(r=0.86, p<0.001). 
 
 
 
(a) 
 
 
 
 
 
 
 
 
 
 
 
(b) 
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Fig.3. Dose–response relationships of primary outcome change from baseline (y-axis shows change in number of repetitions 
between pre- and post-training). (a) Dose–response relationships derived using the repetitions achieved recorded by the objective 
report of repetitions (OBM). Linear r2 = 0.08 and quadratic r2 = 0.15. (b) Dose–response relationships derived using the subjective 
  25 
report of repetitions (SRM). Linear r2 = 0.04 and quadratic r2 = 0.18. (c) Dose–response relationships derived using the target 
repetitions (assigned dose).Linear r2 = 0.00 and quadratic r2 = 0.18. Triangles represent the participants’ mean change in daily 
repetitions between pre- and post-training. The solid, dashed and dotted lines refer to the linear, quadratic and non-parametric 
mathematical models fitted to the data, respectively. The non-parametric curve is just a graphical gauge.  
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<captions for other figures are in file ‘Figs 2 and 3’> 
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Table 1 
Modified Fibonacci sequence (mFBS) dose escalation/de-escalation rules 
Cohort mFBS Dose (D) 
increments 
1 D1 D1 
2 1.00 2D1 
3 0.67 1.67D2 
4 0.50 1.5D3 
5 0.40 1.4D4 
6 0.33 1.33D5 
7 0.33 1.33D6 
8+ 0.33 1.33D7+ 
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Table 2 
Participants’ baseline characteristics and outcome scores by cohort 
 
  All cohorts Cohort 1  Cohort 2  Cohort 3  Cohort 4  Cohort 5  
Baseline characteristics       
Age in years, mean (range) 68 (48 to 81) 69 (66 to 71) 72 (68 to 77) 63 (54 to 71) 60 (48 to 75) 74 (69 to 81) 
Months post stroke, mean (range) 70 (9 to 289) 37 (9 to 67) 124 (18 to 
289) 
78 (12 to 120) 65 (11 to 156)  44 (30 to 54) 
Dominant side affected, % 47 0 0 67 100 67 
Female, % 47 67 0 33 100 33 
Right side affected, % 33 0 33 67 0 67 
Baseline scores, mean (SD)       
Max no. repetitions 23 (19) 17 (17) 25 (12) 25 (39) 17 (19) 33 (3) 
Outcome scores, mean (SD)       
Max no. repetitions 34 (29) 23 (21) 38 (27) 49 (55) 23 (24) 15 (39) 
  29 
SD, standard deviation; max, maximum. 
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Table 3  
Individuals’ adherence to target dose, per cohort, with decisions made on feasibility and efficacy as per primary outcome measure 
 
Cohort Participants Target dose 
(repetitions) 
Repetitions 
performed 
Dose 
feasible 
Primary outcome  
Max no. repetitions  
CanDo Digit Extend 
% change from baseline 
Dose 
beneficial 
1 
001 
50 
51 
Yes 
27 
Yes 002 54 0 
003 56 44 
2 
004 
100 
127 
Yes 
18 
Yes 005 100 91 
006 100 17 
3 
007 
167 
170 
Yes 
480 
Yes 008 172 61 
009 73 600 
4 
010 
251 
217 
No 
32 
NA 011 163 100 
012 140 36 
5 
013 
209 
209 
Yes 
14 
Yes 014 207 25 
015 72 77 
NA, not applicable. 
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Box 1: Requirements for the model training task 
 
 Similarity with repetitive training used in experimental studies involving animal models. 
 Relevant to task-specific training to enhance upper limb recovery after stroke. 
 Performance parameters are recordable. 
 Task challenging but achievable for each participant but with minimal variation. 
 Can be undertaken in the home environment without the researcher present. 
 Novel for most participants to minimise confounding effects of prior training. 
 
 
 
 
 
 
 
Cohort 1  
start  dose 
Cohort 2+ 
refined dose 
START 
STOP 
Repeat 
dose 
Decrease dose by 
50% of previous 
increase 
Increase dose 
Dose 
achieved by 0 
of 3? 
Dose 
tolerable? 
Dose 
beneficial? 
Decrease 
in benefit measure 
for 2 of 3? 
2nd consecutive 
at same dose? 
 
2nd consecutive 
with no positive outcome  
change for 2/3? 
Change in 
dose ≥10% of  
last beneficial  
dose>? 
NO 
NO 
YES 
NO 
NO 
YES 
NO 
YES 
NO 
NO 
YES 
YES 
YES 
YES 
